DCTH

+ Watchlist + Portfolio

Delcath Systems, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $17.15
52-Week Range: $8.12 – $17.42
Market Cap: $581.20M
P/E (TTM): 1675.00
EPS (TTM): 0.01
Dividend Yield: —

Advanced Metrics

Price/Book: 4.79
PEG Ratio: 1.60
Return on Equity: 0.47%
Return on Assets: -0.89%
Gross Margin: 87.05%
Operating Margin: 8.22%
Profit Margin: 0.56%
Current Ratio: 9.83
Debt/Equity: 0.02
Total Debt: $2.46M
Free Cash Flow: $18.12M
Revenue Growth: 20.60%
Earnings Growth: 0.00%
Enterprise Value: $488.11M

DCTH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.72M	$2.06M	$37.20M	$85.23M
Cost of Revenue	$686.00K	$635.00K	$6.19M	$11.80M
Gross Profit	$2.03M	$1.43M	$31.02M	$73.43M
Research & Development	$18.58M	$17.50M	$13.87M	$29.25M
Selling, General & Admin	$17.30M	$22.11M	$29.55M	$43.53M
Operating Expenses	$35.89M	$39.61M	$43.43M	$72.77M
Operating Income	-$33.85M	-$38.18M	-$12.41M	$660.00K
EBITDA	-$33.69M	-$37.78M	-$12.18M	$1.01M
Pretax Income	-$36.51M	-$47.68M	-$26.39M	$3.51M
Income Tax	—	—	$0.00	$810.00K
Net Income	-$36.51M	-$47.68M	-$26.39M	$2.70M
Diluted EPS	-4.12	-2.94	-0.93	0.07
Diluted Shares	16.23M	16.23M	28.51M	35.82M

DCTH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$7.67M	$12.65M	$32.41M	$43.45M
Receivables	$366.00K	$483.00K	$11.06M	$12.94M
Inventory	$2.00M	$3.32M	$6.93M	$10.25M
Current Assets	$16.16M	$37.16M	$73.76M	$119.53M
Total Assets	$17.86M	$38.61M	$76.59M	$123.63M
Current Liabilities	$14.73M	$16.45M	$6.14M	$10.95M
Long-Term Debt	$7.84M	—	—	—
Total Debt	$15.87M	$10.19M	$1.04M	$936.00K
Total Liabilities	$23.72M	$22.84M	$7.84M	$12.41M
Retained Earnings	-$457.48M	-$505.16M	-$531.55M	-$528.85M
Shareholders' Equity	-$5.86M	$15.78M	$68.75M	$111.22M
Working Capital	$1.42M	$20.71M	$67.62M	$108.58M
Net Debt	$8.02M	—	—	—

DCTH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$24.95M	-$31.25M	-$18.68M	$22.52M
Capital Expenditure	-$209.00K	-$58.00K	-$559.00K	-$1.55M
Free Cash Flow	-$25.16M	-$31.31M	-$19.24M	$20.97M
Depreciation & Amortisation	$132.00K	$399.00K	$229.00K	$349.00K
Stock-Based Compensation	$7.94M	$8.15M	$9.77M	$24.23M
Investing Cash Flow	-$209.00K	-$19.71M	-$981.00K	-$26.59M
Financing Cash Flow	$10.14M	$51.78M	$39.41M	$15.05M
Share Repurchases	—	—	$0.00	-$6.00M
Net Change in Cash	-$15.02M	$818.00K	$19.75M	$10.97M

DCTH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$19.78M	$24.16M	$20.56M	$20.73M	$24.99M
Cost of Revenue	$2.85M	$3.32M	$2.62M	$3.01M	$3.74M
Gross Profit	$16.94M	$20.84M	$17.94M	$17.72M	$21.26M
Research & Development	$5.01M	$6.88M	$7.99M	$9.37M	$9.82M
Selling, General & Admin	$11.29M	$11.37M	$10.34M	$10.53M	$13.07M
Operating Expenses	$16.30M	$18.25M	$18.33M	$19.90M	$22.89M
Operating Income	$642.00K	$2.59M	-$388.00K	-$2.18M	-$1.64M
EBITDA	$709.00K	$2.62M	-$242.00K	-$2.08M	-$1.51M
Pretax Income	$1.26M	$3.21M	$375.00K	-$1.33M	-$908.00K
Income Tax	$195.00K	$508.00K	-$455.00K	$562.00K	$162.00K
Net Income	$1.07M	$2.70M	$830.00K	-$1.90M	-$1.07M
Diluted EPS	0.03	0.07	0.02	-0.05	-0.03
Diluted Shares	39.51M	40.26M	40.06M	36.45M	36.02M

DCTH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$12.78M	$34.42M	$41.81M	$43.45M	$41.31M
Receivables	$14.38M	$16.77M	$15.56M	$12.94M	$15.26M
Inventory	$7.13M	$10.52M	$10.74M	$10.25M	$9.81M
Current Assets	$84.35M	$113.48M	$120.61M	$119.53M	$120.27M
Total Assets	$87.32M	$116.88M	$124.30M	$123.63M	$124.84M
Current Liabilities	$5.29M	$10.44M	$8.01M	$10.95M	$10.70M
Total Debt	$1.02M	$993.00K	$965.00K	$936.00K	$907.00K
Total Liabilities	$7.09M	$11.89M	$9.45M	$12.41M	$12.13M
Retained Earnings	-$530.48M	-$527.78M	-$526.95M	-$528.85M	-$529.92M
Shareholders' Equity	$80.23M	$104.99M	$114.85M	$111.22M	$112.71M
Working Capital	$79.06M	$103.05M	$112.60M	$108.58M	$109.57M

DCTH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$2.20M	$7.29M	$4.77M	$8.25M	$857.00K
Capital Expenditure	-$140.00K	-$398.00K	-$459.00K	-$550.00K	-$570.00K
Free Cash Flow	$2.06M	$6.89M	$4.31M	$7.70M	$287.00K
Depreciation & Amortisation	$67.00K	$27.00K	$146.00K	$109.00K	$131.00K
Stock-Based Compensation	$6.86M	$7.21M	$5.65M	$4.51M	$4.95M
Investing Cash Flow	-$25.15M	-$415.00K	-$466.00K	-$561.00K	-$571.00K
Financing Cash Flow	$3.25M	$14.64M	$3.10M	-$5.94M	-$2.38M
Share Repurchases	$0.00	—	—	—	-$3.00M
Net Change in Cash	-$19.69M	$21.52M	$7.41M	$1.74M	-$2.10M

Market Snapshot

About

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology treatments. The company's primary technology is a liver-directed chemotherapy delivery system designed to administer high-dose chemotherapy directly to liver tumors while minimizing systemic exposure. Delcath has received regulatory approvals in Europe for its CHEMOSAT Delivery System for treating metastatic melanoma with liver involvement. The company continues to pursue clinical development and commercialization opportunities for its proprietary platform.